INTRODUCTION
============

Obesity continues to be a significant problem worldwide and is associated with comorbidities such as diabetes, hypertension, dyslipidemia, obstructive sleep apnea, and non-alcoholic fatty liver disease \[[@b1-ce-2018-153]\]. Treatment options for obesity include lifestyle interventions, pharmacotherapy, and bariatric surgery. Among these, the most successful and durable strategy is bariatric surgery. Experimental evidence demonstrates that bypass surgery may affect glucose metabolism, highlighting the significance of small bowel manipulation in bariatric and metabolic therapies \[[@b2-ce-2018-153]\]. Roux-en-Y gastric bypass (RYGB) surgery has been demonstrated to affect weight loss and improve glucose intolerance in patients with type 2 diabetes mellitus (T2DM) \[[@b3-ce-2018-153],[@b4-ce-2018-153]\].

Endoscopic bariatric therapies (EBTs) enable patients to lose weight by targeting the stomach or small bowel, similarly to bariatric surgery but with less invasiveness and better safety \[[@b5-ce-2018-153],[@b6-ce-2018-153]\]. EBTs could be an alternative treatment for patients with mild to moderate obesity who have not been able to lose weight with nonsurgical therapy and who do not qualify for bariatric surgery. This review focuses on small bowel EBTs, including endoluminal sleeves, the incisionless anastomosis system, and resurfacing of the duodenal mucosa.

ENDOLUMINAL SLEEVES
===================

Two hypotheses have been proposed to explain the effect of endoluminal sleeves on T2DM. The "foregut hypothesis" proposes that the exclusion of the "foregut", duodenum and proximal jejunum, and the accelerated delivery of poorly digested nutrients to the "hindgut" possibly prevent secretion of a putative signal that promotes insulin resistance and T2DM \[[@b7-ce-2018-153]-[@b10-ce-2018-153]\]. The "hindgut hypothesis" assumes that diabetes control results from the accelerated delivery of nutrients to the distal intestine, enhancing a physiological signal that improves glucose metabolism and weight loss by accentuation of an "ileal brake" \[[@b11-ce-2018-153]-[@b14-ce-2018-153]\]. The weight management of the ileal brake is based on several findings. First, activation of the ileal brake causes a reduction in food intake and an increase in satiety. Second, the increased exposure of the ileum to nutrients by endoscopic or surgical procedures causes weight loss and improves glucose control. Third, the appetite-lowering effect of chronic ileal brake activation seems to be sustained over time \[[@b15-ce-2018-153]\].

Duodenal-jejunal bypass liner
-----------------------------

EndoBarrier (GI Dynamics, Lexington, MA, USA; [Fig. 1A](#f1-ce-2018-153){ref-type="fig"}) is a 60-cm-long, highly flexible, Teflon fluoropolymer duodenal-jejunal bypass liner (DJBL). The device is deployed under endoscopic and fluoroscopic guidance with a self-expanding nitinol anchor in the duodenal bulb, and the liner extends into the proximal jejunum, allowing nutrients to pass directly from the stomach into the jejunum. Pancreatic enzymes and bile flow down between the liner and the intestinal wall, mixing with nutrients at the jejunum. This device is placed for 3--12 months and then removed endoscopically.

Both the exclusion of the duodenal-jejunal nutrient flow and rapid delivery of undigested nutrients and bile acid to the distal small intestine are thought to play roles in the weight loss and improvement of glucose metabolism \[[@b2-ce-2018-153],[@b16-ce-2018-153]\]. Similar to the foregut hypothesis, exclusion of the proximal small intestine from coming into contact with nutrients potentially downregulates the production of anti-incretins, which leads to the mitigation of insulin resistance \[[@b17-ce-2018-153]\]. Furthermore, early delivery of bile and nutrients to the distal small intestine stimulates L cells in the terminal ileum and proximal colon to secrete gut hormones such as glucagon-like peptide 1 (GLP-1) and peptide YY (PYY), which are implicated in the incretin effect and satiety \[[@b18-ce-2018-153],[@b19-ce-2018-153]\].

The effectiveness and safety of DJBL have been assessed over several studies, which have demonstrated significant weight loss and improvements in several metabolic parameters. To date, five published randomized controlled trials have compared DJBL with a placebo or control arm ([Table 1](#t1-ce-2018-153){ref-type="table"}) \[[@b20-ce-2018-153]-[@b24-ce-2018-153]\]. A previous meta-analysis reported that patients who undergo DJBL interventions achieve an excess weight loss (EWL) of 35.3% (95% confidence interval \[CI\], 24.6%--46.1%) at 12 months \[[@b25-ce-2018-153]\]. Another meta-analysis, which include four randomized controlled studies, showed that DJBL resulted in 12.6% EWL (95% CI, 9.0%--16.2%) as compared with diet modification in patients with obesity and T2DM \[[@b26-ce-2018-153]\]. In addition to the short-term clinical outcomes, a few studies have shown that EWL may remain detectable 6 to 12 months after device removal \[[@b24-ce-2018-153]\]. However, over the long term, patients may gain weight, with reportedly 74% of patients experiencing weight regain within the first 6 months after device removal \[[@b16-ce-2018-153],[@b27-ce-2018-153],[@b28-ce-2018-153]\].

The device also appears to have an impact on glycemic control, as demonstrated by reductions in glycated hemoglobin (HbA1c) levels. A recent meta-analysis assessed the effect of DJBL on glycemic control in patients with obesity and T2DM and showed that DJBL was associated with an EWL of 36.9% (95% CI, 29.2%--44.6%) and a decrease in HbA1c level of 1.3% (95% CI, 1.0%--1.6%) relative to control subjects \[[@b19-ce-2018-153]\]. In addition, DJBL was associated with increases in GLP-1 and PYY levels, and a decrease in glucose-dependent insulinotropic peptide level, which suggests mechanisms similar to RYGB.

Adverse events reported with the DJBL include abdominal pain, nausea, and vomiting. Almost all patients with DJBL have been reported to experience mild-to-moderate adverse events, which can be improved with conservative management \[[@b26-ce-2018-153]\]. Associated serious adverse events include sleeve migration (4.9%), gastrointestinal bleeding (3.9%), sleeve obstruction (3.4%), liver abscess (0.1%), cholangitis (0.1%), acute cholecystitis (0.1%), and esophageal perforation (0.1%) \[[@b25-ce-2018-153]\]. Early device removal has been required in up to 38% of patients, due to bleeding, migration, obstruction, or abdominal pain \[[@b20-ce-2018-153]-[@b24-ce-2018-153]\]. No case of procedure-related mortality has been reported. Although DJBL is a promising treatment option for patients with obesity and T2DM hitherto and showed acceptable safety profiles, the risks and benefits of the procedure should be weighed carefully during clinical practice \[[@b29-ce-2018-153],[@b30-ce-2018-153]\].

Gastroduodenojejunal bypass sleeve
----------------------------------

The ValenTx gastroduodenojejunal bypass sleeve (ValenTx Endoluminal Bypass, Hopkins, MN, USA; [Fig. 1B](#f1-ce-2018-153){ref-type="fig"}) is a 120-cm-long fluoropolymer sleeve designed to be anchored to the gastroesophageal junction. The implantation procedure is both endoscopic and laparoscopic, with laparoscopy allowing for external visualization to ensure transmural anchor placement at the gastroesophageal junction. The sleeve extends from the stomach to the jejunum, allowing nutrients to bypass the stomach, duodenum, and proximal jejunum. The device can be removed endoscopically through endoscopic ligation of the anchoring sutures.

Early experiences with the device in morbidly obese patients have shown substantial weight loss and metabolic improvements \[[@b31-ce-2018-153],[@b32-ce-2018-153]\]. In one study, the device was successfully delivered in 22 (92%) of 24 patients, with five patients (23%) requiring early removal of the device because of odynophagia \[[@b31-ce-2018-153]\]. The device resulted in 39.7% EWL (range, 27%--64%) at 3 months, and 7 patients with T2DM had normal blood glucose levels throughout the trial. In another study, initial device implantation was successful in all patients, and only two patients (17%) required early removal due to dysphagia or odynophagia \[[@b32-ce-2018-153]\]. In six of 10 patients whose sleeves were fully attached throughout the study period, the mean EWL was 54% at 12 months. In the remaining four patients, partial cuff detachment was observed at follow-up endoscopy, and the mean EWL was lower than that of the patients with full attachment. Four patients with T2DM showed improvement in HbA1c and fasting blood glucose levels. No other significant adverse events were encountered during follow-up.

INCISIONLESS ANASTOMOSIS SYSTEM
===============================

Dual-path enteral bypass is achieved endoscopically by creating a jejuno-ileal bypass using self-assembling magnets (Incisionless Magnetic Anastomosis System; GI Windows, Boston, MA, USA; [Fig. 1C](#f1-ce-2018-153){ref-type="fig"}) \[[@b33-ce-2018-153]\]. This system requires simultaneous enteroscopy and colonoscopy, whereby the magnets are deployed from the working channel of each endoscope. Once deployed and coupled, the octagonally shaped magnets create a large-bore compression anastomosis that allows partially digested contents to pass rapidly to the distal ileum. The coupled magnets pass spontaneously through the stool; therefore, the dual-path enteral bypass system does not require further intervention for device removal. A preliminary study of 10 morbidly obese patients with a mean body mass index of 41 kg/m^2^ demonstrated the technical feasibility and durable patency of dual-pass enteral bypass \[[@b34-ce-2018-153]\]. This bypass strategy has resulted in 10.6% total weight loss and 28.3% EWL at 6 months. In addition, this system has been associated with significant reductions in HbA1c and fasting blood glucose levels after 6 months in patients with prediabetes or T2DM.

DUODENAL MUCOSAL RESURFACING
============================

Duodenal mucosal resurfacing (DMR; Fractyl, Lexington, MA, USA; [Fig. 1D](#f1-ce-2018-153){ref-type="fig"}) is an endoscopic procedure that achieves hydrothermal ablation of the duodenal mucosa. The procedure consists of duodenal sizing, saline expansion of the submucosal space, and hydrothermal ablation of superficial layers to allow a restoration of a normal mucosal interface that corrects abnormal metabolic signaling. A polyethylene terephthalate balloon catheter is introduced into the duodenum, and circumferential mucosal lifting is performed along the length of the postpapillary duodenum. After removal of the initial catheter, a 2.0-cm-long balloon on the catheter is introduced and inflated with heated water for circumferential ablation of the duodenal mucosa. Under direct endoscopic visualization, circumferential thermal ablations of about 10 seconds each are applied at temperatures of approximately 90°C to obtain the desired length of mucosal ablation.

The first human study of DMR with varying lengths showed favorable short-term outcomes with acceptable tolerability \[[@b35-ce-2018-153]\]. Both long- (≥9 cm) and short-segment DMR (\<6 cm) resulted in a significant improvement in the glycemic indexes of patients with T2DM over 6 months of follow-up. The HbA1c level decreased by a mean of 1.2%±0.3% in the full cohort, and this effect was greater in long-segment DMR than in short-segment DMR. The most common adverse event was transient abdominal pain after the procedure. Duodenal stenosis occurred in three patients 2--6 weeks after the procedure and was treated successfully with endoscopic balloon dilation. A modest effect on body weight was observed during the 6-month period, which suggests that the metabolic effect was unlikely to be related to the alterations in body weight.

CONCLUSIONS
===========

Small bowel EBTs have produced promising results in weight loss and metabolic parameters, with reasonable safety profiles. EBTs are more effective than lifestyle modification and are less invasive and thus safer than bariatric surgery. However, weight loss produced by EBTs is less durable than that achieved by bariatric surgery, and maintenance strategies are necessary. A multidisciplinary approach to EBT use in conjunction with lifestyle interventions and medications may be beneficial to optimize long-term treatment outcomes. Elucidating the mechanisms underlying the effects of small bowel EBTs may provide more information, including clues to guide device and procedural improvements.
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###### 

Randomized Controlled Studies That Assessed Clinical Outcomes of Duodenaljejunal Bypass Liner

  Study Author (year)                Number^[a)](#tfn1-ce-2018-153){ref-type="table-fn"}^   Age, yr             BMI, kg/m^2^            Duration, weeks   HbA1c, % (preoperative)   HbA1c, % (postoperative)                                             %EWL
  ---------------------------------- ------------------------------------------------------ ------------------- ----------------------- ----------------- ------------------------- -------------------------------------------------------------------- -----------------------------------------------------------------------
  Rodriguez et al. (2009) \[20\]     18                                                                                                 24                                                                                                               
   DJBL                              12 (12)                                                45±7                38.9±5.9                                  9.2±1.7                   −2.4±0.7^[b)](#tfn2-ce-2018-153){ref-type="table-fn"}^               
   Sham                              6 (6)                                                  51±13               39.0±7.2                                  9.0±2.0                   −0.8±0.4^[b)](#tfn2-ce-2018-153){ref-type="table-fn"}^               
  Tarnoff et al. (2009) \[21\]       39                                                                                                 12                                                                                                               
   DJBL                              25 (3)                                                 38.0±10.1           42.0±5.1                                  6.6 (range, 5.5--7.8)     6.0 (range, 5.8--7.1)                                                22.1±8^[\*](#tfn3-ce-2018-153){ref-type="table-fn"}^
   Control                           14 (1)                                                 43.0±10.6           40.0±3.5                                  12.6                      7.8                                                                  5.3±6.6^[\*](#tfn3-ce-2018-153){ref-type="table-fn"}^
  Gersin et al. (2010) \[22\]        47                                                                                                 12                                                                                                               
   DJBL                              21 (14)                                                45±7                46±5                                      7.7±2.5                   7.2±2.1                                                              11.9±1.4^[\*](#tfn3-ce-2018-153){ref-type="table-fn"}^
   Sham                              26 (12)                                                43±10               46±6                                      7.6±1.3                   6.8±0.2                                                              2.7±2.0^[\*](#tfn3-ce-2018-153){ref-type="table-fn"}^
  Schouten et al. (2010) \[23\]      37                                                                                                 12                                                                                                               
   DJBL                              26 (8)                                                 40.9 (20--59)       48.9 (39--60)                             8.8±1.7                   7.7±1.8                                                              19.0±10.9^[\*\*](#tfn4-ce-2018-153){ref-type="table-fn"}^
   Control                           11 (2)                                                 41.2 (19--57)       49.2 (37--60)                             7.3±0.1                   6.9±0.6                                                              6.9±6.1^[\*\*](#tfn4-ce-2018-153){ref-type="table-fn"}^
  Koehestanie et al. (2014) \[24\]   73                                                                                                 24                                                                                                               
   DJBL                              34 (34)                                                49.5 (IQR 42--58)   34.6 (IQR 32.4--38.1)                     8.3 (IQR 7.7--9.0)        7.0 (IQR 6.4--7.5)^[\*\*](#tfn4-ce-2018-153){ref-type="table-fn"}^   32.0 (IQR 22.0--46.7)^[\*\*](#tfn4-ce-2018-153){ref-type="table-fn"}^
   Control                           39 (39)                                                49.0 (IQR 44--55)   36.8 (IQR 32.6--42.0)                     8.3 (IQR 7.7--8.9)        7.9 (IQR 6.6--8.3)^[\*\*](#tfn4-ce-2018-153){ref-type="table-fn"}^   16.4 (IQR 4.1--34.6)^[\*\*](#tfn4-ce-2018-153){ref-type="table-fn"}^

Data are presented as numbers, means±standard deviation, or median (range).

BMI, body mass index; HbA1c, glycated hemoglobin; EWL, excess weight loss; DJBL, duodenal-jejunal bypass liner; IQR, interquartile range.

Parenthesis: number of patients with diabetes mellitus.

Change in HbA1c level.

p\<0.001,

p\<0.05.
